Pfizer Inc
Change company Symbol lookup
Select an option...
PFE Pfizer Inc
CMCO Columbus McKinnon Corp
PPBI Pacific Premier Bancorp Inc
CAT Caterpillar Inc
JHI John Hancock Investors Trust
SLGN Silgan Holdings Inc
GBX Greenbrier Companies Inc
GOOG Alphabet Inc
PUCKU Goal Acquisitions Corp
PRGO Perrigo Company PLC
Go

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.

Closing Price
$50.91
Day's Change
-0.17 (-0.33%)
Bid
--
Ask
--
B/A Size
--
Day's High
51.33
Day's Low
50.48
Volume
(Average)
Volume:
16,881,642

10-day average volume:
17,852,916
16,881,642

Company Profile

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.

Valuation Ratios

Price/Earnings (TTM)
9.69x
Price/Sales (TTM)
2.88x
Price/Book (MRQ)
3.09x
Price/Cash Flow (TTM)
8.18x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend

Short Interest

November 2022
Current Month
70.0M
Previous Month
54.7M
Percent of Float
1.25%
Days to Cover
3.1132 Days

Share Information

PFE is in a share class of common stock
Float
5.6B
Shares Outstanding
5.6B
Institutions Holding Shares
3,829
68.10%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Albert BourlaChmn.
  • David M. DentonCFO
  • Angela HwangCorp.Exec.
  • Lidia FonsecaExec.VP
  • Rady A. JohnsonExec.VP

Address

Insider Trading

During the most recent quarter, 4K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.